Health Care [ 4/12 ] | Pharmaceuticals [ 25/74 ]
NASDAQ | Common Stock
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, and commercializing pharmaceutical products for rare diseases.
The company offers INCRELEX, treatment for children who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD); ALKINDI SPRINKLE, as a replacement therapy for Adrenocortical Insufficiency ("AI") in children under 17 years of age, and accurate dosing for newborns and children with AI; GALZIN, as a maintenance treatment for patients with Wilson Disease who have been initially treated with a chelating agent; PKU GOLIKE, medical formula for the dietary management of phenylketonuria ("PKU"); Carglumic Acid, treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase ("NAGS") deficiency; Betaine Anhydrous, for the treatment of homocystinuria; Nitisinone for the treatment of tyrosinemia type 1; and Amglidia for the treatment of neonatal diabetes mellitus products.
It also develops ET-600 for the treatment of central diabetes insipidus; ET-700 for the treatment of treatment of Wilson disease; ET-800; Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis.
Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 18, 25 | -0.03 Increased by +66.67% | -0.00 Decreased by -809.09% |
| Nov 13, 24 | 0.02 Increased by +200.00% | -0.01 Increased by +300.00% |
| Aug 9, 24 | -0.12 Decreased by -180.00% | -0.07 Decreased by -71.43% |
| May 9, 24 | -0.03 Increased by +70.00% | -0.07 Increased by +57.14% |
| Mar 14, 24 | -0.09 Decreased by -325.00% | -0.04 Decreased by -125.00% |
| Nov 9, 23 | -0.02 Increased by +83.33% | -0.10 Increased by +80.00% |
| Aug 10, 23 | 0.15 Increased by +350.00% | -0.09 Increased by +266.67% |
| May 11, 23 | -0.10 Increased by +52.38% | -0.14 Increased by +28.57% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 11.65 M Increased by +59.26% | -598.00 K Increased by +73.49% | Decreased by -5.13% Increased by +83.36% |
| Sep 30, 24 | 10.32 M Increased by +46.90% | 627.00 K Increased by +208.29% | Increased by +6.07% Increased by +173.72% |
| Jun 30, 24 | 9.07 M Decreased by -24.36% | -3.04 M Decreased by -166.70% | Decreased by -33.51% Decreased by -188.19% |
| Mar 31, 24 | 7.97 M Increased by +50.19% | -811.00 K Increased by +72.15% | Decreased by -10.18% Increased by +81.46% |
| Dec 31, 23 | 7.31 M Decreased by -13.94% | -2.26 M Decreased by -347.37% | Decreased by -30.85% Decreased by -387.45% |
| Sep 30, 23 | 7.03 M Increased by +118.33% | -579.00 K Increased by +81.88% | Decreased by -8.24% Increased by +91.70% |
| Jun 30, 23 | 12.00 M Increased by +63.05% | 4.56 M Increased by +392.62% | Increased by +38.00% Increased by +279.47% |
| Mar 31, 23 | 5.30 M Increased by +143.75% | -2.91 M Increased by +47.75% | Decreased by -54.90% Increased by +78.56% |